Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib versus best available therapy in myelofibrosis
NL-OMON41280Phase 3Active, not recruiting
- Sponsor
- CTI BioPharma Corp.
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pacritinib in myelofibrosis (MF), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and 2 more (2 arms), sponsored by CTI BioPharma Corp. Primary endpoint: Spleen volume response at Week 24. Started Jun 2013; status: active, not recruiting.
02
Drugs
pacritinib
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)myeloproliferative disorder (MPD)
Beyond the preview
Go deeper on NL-OMON41280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41280.